Atox Bio of Israel raises $ 30 million in a round led by Arix Bioscience – tech2.org

Atox Bio of Israel raises $ 30 million in a round led by Arix Bioscience



[ad_1]

JERUSALEM, Dec 4 (Reuters) – Israeli biotech firm Atox Bio said on Monday it raised $ 30 million to further develop its leading product as a kidney treatment, in a fundraising round run by Arix Bioscience, based in the United Kingdom.

Atox Bio hopes to move forward with the clinical development of its Reltecimod immune system treatment for acute kidney injury, which he said is an important unmet clinical need in critically ill patients with serious infections.

Reltecimod is already being studied in a phase 3 clinical trial in patients with soft tissue necrotizing infections, also known as meat-eating bacteria. Atox Bio said it plans to start a Phase 2 study in Acute Kidney Injury in 2018.

Arix Bioscience invested $ 8 million. Other investors in the round included Adams Street Partners, Japanese chemical company Asahi Kasei Corp and existing investors SR One, OrbiMed, Lundbeckfonden Ventures, Becker and Integra Holdings. (Reporting by Ari Rabinovitch, Edition by Tova Cohen)

Our standards: The principles of Thomson Reuters trust.
[ad_2]
Source link

Leave a Reply

Your email address will not be published.